The PLI scheme focuses on incentivizing a strategic shift towards high-value, innovative products such as biologics, complex generics, and specialty formulations
OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors
Its lead product, Dasynoc, is awaiting FDA approval with a PDUFA date of October 7, 2025
AINU is set to accelerate its expansion footprint, enhance operational capabilities
The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), KENGREAL of Chiesi USA
NorUDCA is the first?in?class treatment for Non?alcoholic Fatty Liver Disease (NAFLD) in India
Vasograin Plus represents a major advancement in the treatment of migraine
The savings will be fully reinvested to support new product launches and its pipeline across multiple therapeutic areas
Subscribe To Our Newsletter & Stay Updated